Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press59910.17650/1726-9776-2016-12-4-81-86DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыSalvage high-dose-rate brachytherapy for local prostate cancer recurrence after radical radiotherapyСпасительная брахитерапия высокой мощности дозы при местном рецидиве рака предстательной железы после радикальных радиотерапевтических методов леченияSolodkiyV. A.СолодкийВ. А.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117485 Москва, ул. Профсоюзная, 86

mailbox@rncrr.rssi.ruPavlovA. Yu.ПавловА. Ю.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117485 Москва, ул. Профсоюзная, 86

pavlovdetur@mail.ruTsybul’skiyA. D.ЦыбульскийА. Д.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117485 Москва, ул. Профсоюзная, 86

vracheg@mail.ruRussian Scientific Center of Roentgenoradiology, Ministry of Health of RussiaФГБУ «Российский научный центр рентгенорадиологии» Минздрава России3012201612481862808201608112016https://oncourology.abvpress.ru/oncur/article/view/599

Studies salvage interstitial radiation therapy for recurrent prostate cancer, launched at the end of the XX century. In recent years, more and more attention is paid to high-dose-rate brachytherapy (HDR-BT) as a method of treating local recurrence.

The purpose of research – preliminary clinical results of salvage high-dose-rate brachytherapy applied in cases of suspected local recurrence or of residual tumour after radiotherapy.

Preliminary findings indicate the possibility of using HDR-BT, achieving local tumor control with low genitourinary toxicity.

Исследования спасительной внутритканевой лучевой терапии при рецидивах рака предстательной железы были начаты в конце XX века. В последнее время все больше внимания уделяется брахитерапии высокой мощности дозы (high dose rate brachytherapy, HDR-BT) в качестве метода достижения локального контроля над опухолью.

Цель исследования – первичный анализ лечения больных раком предстательной железы, которым была проведена спасительная HDR-BT по поводу подтвержденного локального рецидива после радиотерапевтических методов лечения.

Предварительные результаты исследования говорят о возможности использования HDR-BT с достижением локального контроля над опухолью при низкой генитоуринарной и гастроинтерстициальной токсичности.

prostate cancerprostate cancer recurrencesalvage brachytherapylife-saving brachytherapyhigh dose brachytherapyhigh dose rate brachytherapyinterstitial radiation therapyprostate-specific antigenрак предстательной железырецидив рака предстательной железысальважная брахитерапияспасительная брахитерапиявысокодозная брахитерапиявысокомощностная брахитерапиявнутритканевая лучевая терапияпростатический специфический антиген1. Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI: 10.1093/jrr/rrw003. PMID: 26983988.Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI: 10.1093/jrr/rrw003. PMID: 26983988.2. Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI: 10.1186/s13014-016-0599-5. PMID: 26911291.Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI: 10.1186/s13014-016-0599-5. PMID: 26911291.3. Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI: 10.1016/j.brachy.2015.12.008. PMID: 26832677.Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI: 10.1016/j.brachy.2015.12.008. PMID: 26832677.4. Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9. PMID: 26785374.Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9. PMID: 26785374.5. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066–73.Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066–73.6. Jo Y., Fujii T., Hara R. et al. Salvage highdose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI: 10.1111/j.1464-410X.2011.10519.x. PMID: 21933327.Jo Y., Fujii T., Hara R. et al. Salvage highdose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI: 10.1111/j.1464-410X.2011.10519.x. PMID: 21933327.7. Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI: 10.1159/000371893. PMID: 25765848.Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI: 10.1159/000371893. PMID: 25765848.8. Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;(2):143–9.Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;(2):143–9.9. Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10. PMID: 9886580.Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10. PMID: 9886580.10. Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI: 10.1111/j.1464-410X.2009.08445.x. PMID: 19245439.Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI: 10.1111/j.1464-410X.2009.08445.x. PMID: 19245439.11. Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI: 10.1016/j.ijrobp.2006.10.012. PMID: 17197119.Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI: 10.1016/j.ijrobp.2006.10.012. PMID: 17197119.12. Nguyen P.L., Chen R.C., Clark J.A. et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: a prospective Phase II study. Brachytherapy 2009;8(4):345–52. DOI: 10.1016/j.brachy.2009.01.004. PMID: 19428311.Nguyen P.L., Chen R.C., Clark J.A. et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: a prospective Phase II study. Brachytherapy 2009;8(4):345–52. DOI: 10.1016/j.brachy.2009.01.004. PMID: 19428311.13. Beyer D.C. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 2003;13(2):158–65. DOI: 10.1053/srao.2003.50015. PMID: 12728445.Beyer D.C. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 2003;13(2):158–65. DOI: 10.1053/srao.2003.50015. PMID: 12728445.